Petros Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $5.1M | $5.8M | $6.0M | $7.8M | $9.6M |
| Cost of Revenue | — | — | $1.2M | $1.6M | $2.3M | $1.6M | $4.0M |
| Gross Profit | — | — | $3.9M | $4.2M | $3.7M | $6.2M | $5.5M |
| Gross Margin | — | — | 76.3% | 72.0% | 61.8% | 79.5% | 57.7% |
| Operating Expenses | |||||||
| Research & Development | — | — | $2.6M | $2.4M | $1.7M | $1.8M | $459.6K |
| SG&A Expense | — | $4.6M | $4.6M | $9.3M | $12.2M | $15.6M | $15.7M |
| Operating Income | — | $-4.6M | $-4.6M | $-13.6M | $-19.9M | $-18.0M | $-17.3M |
| Operating Margin | — | — | -90.5% | -233.9% | -332.4% | -231.1% | -180.8% |
| Interest Expense | — | — | $560.9K | $536.1K | $596.0K | $368.7K | $3.1M |
| Pretax Income | — | $-4.5M | $-705.2K | $-8.2M | $-20.0M | $-9.0M | $-22.0M |
| Income Tax Expense | — | $0 | $0 | $0 | — | $0 | $-1.4M |
| Net Income | — | $1.9M | $-14.3M | $-8.2M | $-20.0M | $-9.0M | $-20.6M |
| Net Margin | — | — | -280.1% | -140.2% | -334.4% | -115.0% | -215.3% |
| EPS (Basic) | — | $-1.56 | $-0.96 | $-0.07 | $-0.11 | $-0.09 | $-0.04 |
| EPS (Diluted) | — | $-1.56 | $-0.96 | $-0.07 | $-0.11 | $-0.09 | $-0.04 |
| Shares Outstanding (Basic) | 42.4M | 28.1M | 27.9M | 189.3M | 180.1M | 94.7M | 464.6M |
| Shares Outstanding (Diluted) | 42.4M | 28.1M | 27.9M | 189.3M | 180.1M | 94.7M | 464.6M |
| Dividends Per Share | — | — | — | — | — | — | — |